Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease

Journal of Neuroscience Research

Volumn 92, Issue 8, 2014, Pages 1071-1077

  Botta Orfila, Teresa ^a   Morató, Xavier ^a   Compta, Yaroslau ^a,b   Lozano, Juan José ^c   Falgàs, Neus ^b   Valldeoriola, Francesc ^a,b   Pont Sunyer, Claustre ^a,b   Vilas, Dolores ^a,b   Mengual, Lourdes ^a   Fernández, Manel ^a   Molinuevo, José Luis ^a,b   Antonell, Anna ^a,b   Martí, Maria José ^a,b   Fernández Santiago, Rubén ^a   Ezquerra, Mario ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomarker; Blood; MiRNAs; Parkinson's disease

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 19B; MICRORNA 29A; MICRORNA 29C; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; EXPLORATORY RESEARCH; EXTRACELLULAR MATRIX; FEMALE; FOCAL ADHESION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NERVE PROJECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WNT SIGNALING PATHWAY; AGED; BLOOD; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PILOT STUDY;

ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84902545816     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23377     Document Type: Article

References (48)

1. Alegre-Abarrategui J, Christian H, Mutihac R, Venda LL, Ansorge O, Wade-Martins R. 2009. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 8:4022-4034.
2. Botta-Orfila T, Tolosa E, Gelpi E, Sànchez-Pla A, Martí MJ, Valldeoriola F, Fernández M, Carmona F, Ezquerra M. 2012. Microarray expression analysis in idiopathic and LRRK2 associated Parkinson's disease. Neurobiol Dis 45:462-468.
3. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman J, Hannon GJ, Stebbing J. 2009. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106:15732-15737.
4. Ceman S, Saugstad J. 2011. MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol Ther 130:26-37.
5. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. 2010. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10:173.
6. Chen X, Ba Y, Ma L, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997-1006.
7. Danger R, Pallier A, Giral M, Martinez-Llordella M, Lozano JJ, Degauque N, Sanchez-Fueyo A, Soulillou JP, Brouard S. 2012. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant J Am Soc Nephrol 23:597-606.
8. Dauer W, Ho CC. 2010. The biology and pathology of the familial Parkinson's disease protein LRRK2. Mov Disord 25(Suppl 1):S40-S43.
9. Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wüllner U, Illig T, Sharma M, Gasser T. 2009. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging 30:731-738.
10. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. 2006. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63:377-382.
11. Gehrke S, Imai Y, Sokol N, Lu B. 2010. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637-641.
12. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Youdim MB. 2004. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543-1573.
13. Habig K, Walter M, Poths S, Riess O, Bonin M. 2008. RNA interference of LRRK2 microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9:83-94.
14. Hebert SS, De Strooper B. 2009. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32:199-206.
15. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. 2010. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721-1726.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
17. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E. 2008. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27:2432-2443.
18. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. 2008. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 29:438-445.
19. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. 2009. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 106:13052-13057.
20. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Choon TA. 2012. Plasma-based circulating microRNA biomarkers for Parkinson's disease. J Parkinsons Dis 2:321-331.
21. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. 2007. A microRNA feedback circuit in midbrain dopamine neurons. Science 317:1220-1224.
22. Kosaka N, Iguchi H, Ochiya T. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087-2092.
23. Lau P, De Strooper B. 2010. Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol 21:768-773.
24. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS. 2008. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672-675.
25. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373:2055-2066.
26. Margis R, Rieder CR. 2011. Identification of blood microRNAs associated to Parkinson's disease. J Biotechnol 152:96-101.
27. Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, Mestre T, Coelho M, Rosa MM, Martin ER, Vance JM, Outeiro TF, Wang L, Borovecki F, Ferreira JJ, Oliveira SA. 2011. Convergence of miRNA expression profiling, α-synuclein interaction and GWAS in Parkinson's disease. PLoS One 6:e25443.
28. Mayeux R, Denaro J, Hemenegildo N. 1992. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492-497.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
30. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J. 2009. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64.
31. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. 2010. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017-2020.
32. Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, Kerckaert JP, Pérez-Tur J, Waucquier N, Vanbesien-Mailliot C, Duflot A, Devos D, Defebvre L, Kreisler A, Frigard, B, Destée A, Chartier-Harlin MC. 2011. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 32:1839-1848.
33. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T, Parkinson Study Group-PROGENI investigators. 2005. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365:410-412.
34. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators. 2009. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72:310-316.
35. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. 2009. DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 25:1991-1993.
36. Ragonese P, D'Amelio M, Savettieri G. 2006. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann N Y Acad Sci 1089:373-382.
37. Saba R, Goodman CD, Huzarewich RL, Robertson C. 2008. Booth SA. A miRNA signature of prion induced neurodegeneration. PLoS One 3:e3652.
38. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. 2009. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132:1795-1809.
39. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, Yuasa Y, Kang D, Kim YS, You WC. 2012. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 7:e33608.
40. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. 2006. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 103:2746-2751.
41. Vaday GG, Franitza S, Schor H, Hecht I, Brill A, Cahalon L, Hershkoviz R, Lider O. 2001. Combinatorial signals by inflammatory cytokines and chemokines mediate leukocyte interactions with extracellular matrix. J Leukoc Biol 69:885-892.
42. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
43. Wang G, van der Walt JM, Mayhew G, Li YJ, Züchner S, Scott WK, Martin ER, Vance JM. 2008. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82:283-289.
44. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. 2012. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7:e41561.
45. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT. 2008. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28:1213-1223.
46. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, Ellinger J. 2011. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787.
47. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu, Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Yang C, Zen K, Zhang CY. 2010. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56:1871-1879.
48. Zhang Y, Wu L, Wang Y, Zhang M, Li L, Zhu D, Li X, Gu H, Zhang CY, Zen K. 2012. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem 287:14851-14862.